Key Insights Significant control over GoodRx Holdings by individual investors implies that the general public has ...

GoodRx Holdings Inc. (NASDAQ:GDRX), a leading healthcare technology company specializing in prescription drug discounts and telehealth services, finds itself at a critical juncture. As the company ...

For the third quarter, GoodRx booked revenue of just over $195.3 million, representing growth of 8% over the same period of 2023. Non-GAAP (adjusted) net income was $31.9 million, or $0.08 per share, ...

GoodRx has seen a ~30% increase in its share price this year due to fundamental improvements and raised growth outlook. The company has seen a rebound in pharmacy transactions, leading to two straight ...

GoodRx Holdings Inc. (NASDAQ:GDRX) is one of the oversold stocks to buy now. On January 5, Bank of America analyst Allen Lutz ...

GoodRx offers compelling value after a ~50% stock decline over the past 12 months, trading at just 6.1x FY25 adjusted EBITDA despite recent execution challenges. A new Novo Nordisk partnership for ...

The healthcare services specialist unveiled its first set of quarterly results for this year. It beat on both the top and bottom lines, and slightly increased its guidance for a profitability metric.

GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at ...

GoodRx, which specializes in prescription and telehealth services, saw its revenue rise by almost 3% year-over-year to just under $203 million. Non-GAAP (adjusted) net income also advanced, increasing ...